Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Huang M, Fasching P, Haiderali A, Xue W, Pan W, Karantza V, Yang F, Truscott J, Xin Y, O'Shaughnessy J (2024)

Publication Language: English

Publication Type: Journal article, Review article

Publication year: 2024

Journal

Future Oncology Future Medicine Ltd

Book Volume: 20

Pages Range: 335-348

Journal Issue: 6

DOI: 10.2217/fon-2023-0315

Abstract

Aim: This study evaluated event-free survival (EFS) as a surrogate outcome for overall survival (OS) in neoadjuvant therapy for early-stage triple-negative breast cancer (eTNBC). Methods: Meta-regression analyses based on a targeted literature review were used to evaluate the individual- and trial-level associations between EFS and OS. Results: In the individual-level analyses, 3-year EFS was a significant predictor of 5-year OS (p < 0.01; coefficient of determinations [R2]: 0.82 [95% CI: 0.68-0.91]). Additionally, there was a statistically significant association between the treatment effect on EFS and OS at the trial level (p < 0.001; R2: 0.64 [95% CI: 0.45-0.82]). Conclusion: This study demonstrates significant associations between EFS and OS and suggests that EFS is a valid surrogate for OS following neoadjuvant therapy for eTNBC.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Baylor University Medical Center US United States (USA) (US) Analysis Group Ltd GB United Kingdom (GB) Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) US United States (USA) (US)

How to cite

APA:

Huang, M., Fasching, P., Haiderali, A., Xue, W., Pan, W., Karantza, V.,... O'Shaughnessy, J. (2024). Association between event-free survival and overall survival in early-stage triple-negative breast cancer. Future Oncology, 20(6), 335-348. https://doi.org/10.2217/fon-2023-0315

MLA:

Huang, Min, et al. "Association between event-free survival and overall survival in early-stage triple-negative breast cancer." Future Oncology 20.6 (2024): 335-348.

BibTeX: Download